Promising efficacy signals observed in ongoing DEP® trials, including DEP® cabazitaxel escalation phase
Starpharma today announced that promising efficacy signals have been observed in its ongoing clinical trials for both DEP® cabazitaxel and DEP® docetaxel.
First Asian Regulatory Approvals Received for VivaGel® BV
Starpharma today announced that it has received the first regulatory approvals in South East Asia for VivaGel® BV. Mundipharma will be rolling-out the product in Asia under the brand name BETADINETM BV Gel.
Starpharma commences phase 1/2 DEP® irinotecan trial
Starpharma today announced that it has received the necessary regulatory and ethics approvals and will commence its phase 1/2 clinical trial for DEP® irinotecan. The objectives of the trial are to evaluate the safety, tolerability and pharmacokinetics of DEP® irinotecan to define a recommended phase 2 dose (RP2D), and to determine anti-tumour efficacy of the product in select tumour types. DEP® irinotecan is the third DEP® product to enter the clinic from Starpharma’s internal portfolio with a fourth, partnered DEP® candidate, AZD0466, also set to enter the clinic later this year.
Starpharma CEO speaks with Alan Kohler on The Constant Investor
Starpharma CEO Dr Jackie Fairley speaks with Alan Kohler for online investor publication The Constant Investor, where she discussed the launch of VivaGel BV in Australia and Europe as well as the company’s latest developments in its DEP® portfolio. To listen to the full interview, click here.
Quarterly Cashflow Report
Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 June 2019.
Shareholder Update July 2019
In this issue:
>> VivaGel® BV launched in Europe & Australia; US regulatory progress
>> VivaGel condom launched in Japan by Okamoto
>> DEP® docetaxel & DEP® cabazitaxel clinical trial update; DEP® irinotecan trial start & new data
>> Starpharma signs second commercial oncology agreement with AstraZeneca
>> AstraZeneca highlights AZD0466 at 2019 ASCO meeting & upcoming US FDA IND
>> Patent published for AstraZeneca Bcl2/xL DEP conjugates
>> DEP® radiotherapeutics
>> Outlook, recent news & events
VivaGel® BV launched in Europe
Starpharma today announced that VivaGel® BV has been launched in Europe under the brand name Betadine BVTM. The product has been launched in several countries in Europe, including Germany, with further roll-out in additional European countries during the year.
Starpharma presents at Macquarie Emerging Leaders Forum
Starpharma has been invited to present at the Macquarie Emerging Leaders Corporate Forum in Melbourne. The Macquarie Emerging Leaders Corporate Forum provides Starpharma with an opportunity to present to more than 100 investors from Melbourne and Sydney.
US patent granted for DEP Bcl2/xL inhibitor conjugates
Starpharma announced the first patent for DEP® Bcl2/xL inhibitor conjugates, developed in collaboration with AstraZeneca, has been granted by the US Patent and Trademark Office. These patented DEP® Bcl2/xL inhibitor conjugates combine Starpharma’s innovative DEP® delivery technology with AstraZeneca’s novel Bcl2/xL inhibitors, which are being investigated for treating various cancers, including leukemias.
AstraZeneca inks new deal with Starpharma
|
Biotech trade publication noted Starpharma signed a new development and option agreement with AstraZeneca to progress the development of a DEP® version of one of AstraZeneca's existing oncology medicines. The news builds on a previous deal between the companies related to a multiproduct licence covering novel oncology drug candidates. |
Read the article here.